5 completed, 1 not yet recruiting, 1 suspended, 1 unknown. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Suspended 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow pyronaridine: new trials by email Literature Review of pyronaridine trials Research Report on pyronaridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) MK-7602, Pyronaridine - Healthy | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 24 | 2027-01-04 | 2026-11-05 |
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 192 | 2023-11-28 | 2026-02-06 |
| Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) M5717 330 mg, M5717 500 mg, M5717 660 mg - Acute Malaria | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 38 | 2023-03-29 | 2025-08-27 |
| Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria Pyronaridine, P. falciparum IBSM infection - Malaria,Falciparum, Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 10 | 2022-04-04 | 2025-04-16 |
| A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate Pyronaridine Tetraphosphate, Piperaquine tetraphosphate, Placebo - Healthy | Phase 1 | Completed | Medicines for Malaria Venture | 37 | 2022-02-14 | 2024-05-10 |
| Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Pyronaridine Tetraphosphate/Artesunate, Dihydroartemisinin/Piperaquine, Primaquine Diphosphate - Malaria,Falciparum | Phase 2 / Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 100 | 2019-09-12 | 2020-01-30 |
| Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections Pyronaridine tetraphosphate 180mg:artesunate 60mg - Malaria,Falciparum | Phase 2 | Unknown | Shin Poong Pharmaceutical Co. Ltd. | 300 | 2018-10-03 | 2019-09-30 |
Malaria, Falciparum (5) · Malaria (2) · Acute malaria (1) · Asymptomatic Infections (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1) · Parasitemia (1) · Parasitic Diseases (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Protozoan Infections (1)
Medicines for Malaria Venture (2) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2) · Armaceutica, Inc. (1) · London School of Hygiene and Tropical Medicine (1) · Merck Sharp & Dohme LLC (1) · Shin Poong Pharmaceutical Co. Ltd. (1)
Burkina Faso (2) · The Gambia (2) · Zambia (2) · Australia (1) · Gabon (1) · Kenya (1) · Mali (1) · Mozambique (1) · Netherlands (1) · Senegal (1) · Uganda (1) · United Kingdom (1)
Jang Sik Shin (1) · Renato J Aguilera, PhD (1) · Stephan Chalon, MD PhD (1) · Ulrike Lorch, MD (1)